Review Article
Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC
Table 1
Retrospective studies evaluating TS as predictive biomarker for pemetrexed in NSCLC.
| | Authors | Method for TS quantification |
Number of
participants () | Histology | Results | | | TS-negative | TS-positive | value |
| |
Silva and Cole, 2011 [31] | -score (IHC intensity % pos. neoplastic cells) [28] | 16 | Adenocarcinoma—75% | ORR | 50% | 20% | |
Chen et al.,
2011 [28] | -score |
42 |
Adenocarcinoma—83.8%
Squamous cell carcinoma—16.7% | All patients | | PFS | 4.8 | 3.4 | 0.01 | | OS | 21.4 | 10.0 | 0.09 | | Adenocarcinoma-only patients | | PFS | 4.8 | 3.8 | 0.03 | | OS | 21.4 | 10.0 | 0.03 |
Igawa et al.,
2012 [33] | IHC Intensity |
54 | Adenocarcinoma—96.2%
Other nonsquamous NSCLC—3.8% | ORR | 16.1% | 0.0% | 0.05 | | PFS | 5.8 | 1.6 | 0.03 | | OS | 14.7 | 8.6 | 0.04 |
Sun et al.,
2011 [34] | -score |
193 | Adenocarcinoma—89%
Other nonsquamous NSCLC—11% | ORR | 33.7% | 14.1% | 0.002 | | PFS | 4.1 | 2.0 | 0.001 |
Christoph et al.,
2013 [29] | -score |
196 | Adenocarcinoma—75%
Squamous cell carcinoma—5%
Other NSCLC—20% | PFS | 5.6 | 3.5 | 0.0131 | | OS | 22.5 | 11.5 | 0.0107 |
Chang et al.,
2010 [35] | IHC intensity |
55 | Nonsquamous Cell Carcinoma—87%
Squamous cell carcinoma—13% | PFS | 2.4 | 1.3 | 0.407 | | OS | 9.5 | 6.7 | 0.688 |
Shimizu et al.,
2012 [36] | RT-PCR | 50 | Unavailable | PFS | 18.0 weeks | 13.3 weeks | 0.3001 |
Li et al.,
2013 [37] | SNPs, RT-PCR |
45 | Adenocarcinoma—100% | PFS | 6.8 | 3.8 | 0.036 | | OS | 10.3 | 10.1 | 0.638 |
|
|
ORR: overall response rate, %; PFS: progression free survival, months unless indicated; OS: overall survival, months unless indicated.
Bolded values are for values < or = 0.05.
|
